Nova Patents
PL314481A1

Microencapsulated substituted 3-piperidinyl 1,2-benzoisoxazoles and 1,2-benzoisothiazoles

Abstract

Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release over a period of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an active agent, such as risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing.

Term

Term ended

Projected expiry passed 11 November 2014, 11.9 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

59 members in 31 offices

This recordMember, by publication datePriority claim21 more offices are in the list below

Priority claims4

Priority claims
DocumentOfficeKindDate
15440393United States of AmericaA
15440393United States of AmericaA
154403–––
US19930154403–––

Members59

Family members, oldest first
DocumentOfficeKind
CA2175370A1CanadaA1
WO9513814A1World Intellectual Property Organization (WIPO)A1
AU8142594AAustraliaA
HU9501942D0HungaryD0
FI962111AFinlandA
NO962040D0NorwayD0
ZA949191BSouth AfricaB
NO962040LNorwayL
CZ137396A3CzechiaA3
HUT73501AHungaryA
EP0729357A1European Patent Office (EPO)A1
PL314481A1This recordPolandA1
CN1137756AChinaA
MX9408969AMexicoA
BG100632ABulgariaA
JPH09505286AJapanA
SK64096A3SlovakiaA3
US5688801AUnited States of AmericaA
SG47445A1SingaporeA1
US5770231AUnited States of AmericaA
AU694147B2AustraliaB2
HK1010694A1Hong Kong, ChinaA1
NZ276088ANew ZealandA
US5965168AUnited States of AmericaA
IL111647AIsraelA
US6110921AUnited States of AmericaA
NO309226B1NorwayB1
HU219487BHungaryB
BG63246B1BulgariaB1
CN1074923CChinaC
SK282231B6SlovakiaB6
RU2178695C2Russian FederationC2
MY113298AMalaysiaA
US6368632B1United States of AmericaB1
US2002098233A1United States of AmericaA1
KR100354270B1Republic of KoreaB1
US6544559B2United States of AmericaB2
US2003165571A1United States of AmericaA1
RO119224B1RomaniaB1
CZ293764B6CzechiaB6
US6803055B2United States of AmericaB2
EP0729357B1European Patent Office (EPO)B1
US2005025828A1United States of AmericaA1
ATE288270T1AustriaT1
DE69434258D1GermanyD1
JP3645906B2JapanB2
CL2004001182A1ChileA1
DK0729357T3DenmarkT3
PT729357EPortugalE
SI0729357T1SloveniaT1
ES2236700T3SpainT3
DE69434258T2GermanyT2
CA2175370CCanadaC
FI117122BFinlandB
US2006182810A1United States of AmericaA1
US7118763B2United States of AmericaB2
US2008063721A1United States of AmericaA1
US2008069885A1United States of AmericaA1
US7547452B2United States of AmericaB2